hrcak mascot   Srce   HID

Pregledni rad

NEW PRIMARY MALIGNANCIES AFTER BREAST CANCER DIAGNOSIS: INTERPLAY OF GENETICS, RISK FACTORS AND TREATMENT MODALITIES

Natalija Dedić Plavetić
Marina Barić
Mladen Solarić
Damir Vrbanec

Puni tekst: hrvatski, pdf (272 KB) str. 0-0 preuzimanja: 193* citiraj
APA 6th Edition
Dedić Plavetić, N., Barić, M., Solarić, M. i Vrbanec, D. (2013). NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA. Liječnički vjesnik, 135 (1-2), 0-0. Preuzeto s https://hrcak.srce.hr/172463
MLA 8th Edition
Dedić Plavetić, Natalija, et al. "NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA." Liječnički vjesnik, vol. 135, br. 1-2, 2013, str. 0-0. https://hrcak.srce.hr/172463. Citirano 18.10.2019.
Chicago 17th Edition
Dedić Plavetić, Natalija, Marina Barić, Mladen Solarić i Damir Vrbanec. "NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA." Liječnički vjesnik 135, br. 1-2 (2013): 0-0. https://hrcak.srce.hr/172463
Harvard
Dedić Plavetić, N., et al. (2013). 'NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA', Liječnički vjesnik, 135(1-2), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172463 (Datum pristupa: 18.10.2019.)
Vancouver
Dedić Plavetić N, Barić M, Solarić M, Vrbanec D. NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA. Liječnički vjesnik [Internet]. 2013 [pristupljeno 18.10.2019.];135(1-2):0-0. Dostupno na: https://hrcak.srce.hr/172463
IEEE
N. Dedić Plavetić, M. Barić, M. Solarić i D. Vrbanec, "NOVI PRIMARNI ZLOĆUDNI TUMORI NAKON DIJAGNOZE RAKA DOJKE: MEĐUODNOS NASLIJEĐA, RIZIČNIH ČIMBENIKA I MODALITETA LIJEČENJA", Liječnički vjesnik, vol.135, br. 1-2, str. 0-0, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/172463. [Citirano: 18.10.2019.]

Sažetak
Significant advances in early breast cancer detection and increased quality of care within developed countries resulted in longer than five years survival in almost 90% of women diagnosed and treated for breast cancer. One in twenty women diagnosed with breast cancer will develop a new primary non-breast malignancy within 10 years from initial diagnosis. Mutations in BRCA 1 i 2, RAD51C, MMR, p53, CDKN2A and 113insArg genes are linked with increased risk of breast cancer and other cancer sites. It seems that treatment modalities also play significant role in development of new primary malignancies. Tissues that receive higher doses of radiation during radiotherapy of breast cancer are under increased risk of developing new primary tumor, especially in younger women, ten years after the treatment. Chemotherapy may cause higher incidence of leukemia and myelodysplastic syndrome but lower overall risk for development of other malignancies. Connection between tamoxifen therapy and increased risk of endometrial cancer is well known and confirmed also in recent studies. The true mechanism of cancer development is still unclear. Significance of hereditary factors, possible common environmental risk factors or unwanted side effects of the specific anticancer treatments are yet to be discovered.

Ključne riječi
Breast neoplasms – drug therapy, surgery, radiotherapy; Neoplasms, secondary primary – epidemiology, etiology, genetics; Radiotherapy – adverse effects; Neoplasms, radiation-induced – etiology; antineoplastic agents – adverse effects

Hrčak ID: 172463

URI
https://hrcak.srce.hr/172463

[hrvatski]

Posjeta: 270 *